price perfect
mask growth saw first sign ow thesi play
 key upcom quarter sustain
momentum guidanc flat gm seem assum
acceler mask sale strike us conserv
main area upsid
invest thesis/summari ow share back-
order/manufactur issu resolv start see continu robust
resuppli sale support gm assist posit ep revis
theme support larg instal base growth driven airsens
ii stabl us reimburs environ iii brightre insul market
share drive higher resuppli iv airfit uptak
differ us mask sale growth seen
maintain drive modest improv gm model
benefit higher-gm eur region improv oper leverag via
sg also provid earn tailwind though think
primari catalyst posit ep revis still sustain improv
valuat sit vs coverag increas price target see
on-going oper leverag sg model accordingli
 pa fall respect onward sale model
accordingli lead increas price target impli
fair valu howev remain ow sector rel basi still
prefer stock trade ep vs australian off-shore growth
earner ew-rat ep
assumpt catalyst risk see high single-digit global devic
growth global mid-teen mask growth see gm improv
risk tough comp us devic
growth ii gm fail stabilize/improv iii eurusd fx benefit off-set
opex level likewis higher audusd think result
like show improv resuppli growth gm guidanc could ratchet
appreci support
institut investor all-asia
request ballot
up/downsid price target
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
exhibit statist resm cdi
price target convert cdi
cdi disclaim page morgan stanley research
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
analyst employ non-u affili regist
finra may associ person member may
subject nasd/nys restrict commun
subject compani public appear trade secur held
profit loss
growth pcp
growth pcp
abn extra tax
return asset
return equiti
growth pcp
growth pcp
growth pcp
growth pcp
growth pcp
growth pcp
growth pcp
fy sale
fy ebit
dep amort
gross cash op ns
inc dec wk cap
chg loan
net chg cash
compani data research research estim note provid research coverag list cdi associ underli ordinari share
compani courtesi may includ cdi price target cdi share price aud dollar research report unless otherwis state cdi price target convers calcul use appropri
currenc exchang rate ordinari share versu cdi ratio investor awar calcul take account issu risk associ invest cdi includ limit liquid
vote right dividend volatil currenc exchang rate fluctuat
wide dispers outcom exist
wide dispers outcom exist
equival base case dcf
potenti home sleep test achiev us volum
result mix shift higher-margin apap machin addit small
move mask turn see upsid
appli dcf valuat current forecast includ step
us growth rate associ new product launch decay pa
result combin reduct us mask price reduct
us unit growth remain intern level pa us
medicar rate set
rate ow market share gain
increas instal base support
futur posit momentum sale
consum enhanc confid
long-term sustain ep growth
product launch without rmd
top line would revert market growth rate
less price declin pa
weather cost increas line cpi
growth rate possibl owe
under-penetr osa suffer co-
high growth high-margin mask/
therapi repeat mask/dispos sale
occur
upsid at-hom diagnosi de-
bottleneck clinic pathway
data uptak competitor next-
traction upcom launch three new
exhibit bear bull device/mask asp gm biggest valu driver
mask turn
pressur gm
next
risk achiev price
advers impact us competit bid
continu loss cpap market share
eur usd continu deterior
invest thesis/summari ow share back-
order/manufactur issu resolv see continu robust
driven resuppli sale support gm assist posit ep revis theme
support larg instal base growth driven airsens ii stabl us
reimburs environ iii brightre insul market share drive higher
resuppli iv airfit uptak
differ us mask sale growth seen
least maintain upcom quarter drive modest improv gm
benefit higher-gm eur region improv oper leverag via sg
 also provid earn tailwind though think primari catalyst
posit ep revis still sustain improv product mix
exhibit morgan stanley expect result
exhibit ms chang estim due lower sg
view longer-term-depend dcf valuat methodolog
appropri employ determin forward price target
increas firm convict
compani abl deliv better oper leverag sg
lower sale pa lower sale pa
onward histor volatil ep proven
challeng valu use price-to-earnings methodolog view dcf
appropri method ignor near-term uncertainti emphasis long-term
main dcf assumpt shown exhibit exhibit
debt
equiti
npv cashflow
valu equiti
share issu
ep impli price-to-earnings histor trade multipl
rel absolut basi shown
price target convert cdi
investor awar calcul take account
issu risk associ invest adr includ limit
liquid vote right dividend volatil currenc exchang rate
price target deriv base-cas scenario dcf
assum wacc termin growth rate
post-nucleu sale backwards-compat processor
ii weaken
reimburs restrict us develop eu
ii strengthen
ii disappoint uptak new product
price target deriv base-cas scenario dcf
assum wacc termin growth rate
potenti announc acquisit biotech/vaccines/immunolog
ii industri de-stock possibl price increas
iii uptak kcentra us
lower-than-expect adopt next-gener rcoag product
ii appreci aud usd
iii chang us reimburs environ
